Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vafidemstat - Oryzon Genomics

Next Previous
X
Search
Drug Profile

Vafidemstat - Oryzon Genomics

Alternative Names: ORY-2001

Latest Information Update: 09 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oryzon
  • Developer Institute of Medical and Molecular Genetics; Oryzon
  • Class Amines; Antidementias; Antiparkinsonians; Antipsychotics; Behavioural disorder therapies; Cyclopropanes; Neuroprotectants; Nootropics; Oxadiazoles; Small molecules
  • Mechanism of Action Lysine specific demethylase 1 inhibitors; Monoamine oxidase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Aggression; Alzheimer's disease; Borderline personality disorders; Multiple sclerosis; SARS-CoV-2 acute respiratory disease; Schizophrenia
  • No development reported Autistic disorder; Dementia; Huntington's disease; Parkinson's disease; Telomeric 22q13 Monosomy Syndrome

Most Recent Events

  • 03 Sep 2024 Oryzon Genomics has receive decision to grant communications from the Australian Patent Office for patent applications related to vafidemstat, covering its use for the treatment of aggression and social withdrawal in Australia
  • 03 Sep 2024 Oryzon Genomics has receive decision to grant communications from the Malaysia Patent Office for patent applications related to vafidemstat in Malaysia
  • 03 Sep 2024 Oryzon Genomics has receive decision to grant communications from the Mexican Patent Office for patent applications related to vafidemstat, in Mexico

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top